Table 1.

Baseline laboratory and clinical investigations of the studied groups

	Control group	Single infusion	Repeated infusion	P value
Age (years)	49.43 ± 4.53	49.63 ± 4.58	50.97 ± 4.15	1.00
Male	26 (86.7 %)	25 (83.3 %)	26 (86.7 %)	0.923
Female	4 (13.3 %)	5 (16.7 %)	4 (13.3 %)	0983
Haemoglobin (g/dl)	10.33 ± 1.06	10.2 ± 1.48	10.3 ± 0.77	0.614
TLC (1000/cm)	6.07 ± 1.64	5.17 ± 2.05	6.07 ± 1.14	0.520
Platelets (1000/cm)	104 ± 34	104 ± 55	104 ± 37	0.542
Total bilirubin (N: 0.1–1 mg/dl)	3.19 ± 0.89	3.59 ± 0.79	3.16 ± 0.99	0.326
Serum albumin (N: 3.4–5.2 g/dl)	2.8 ± 0.15	2.57 ± 0.15	2.83 ± 0.16	0.291
INR (N: 1)	1.67 ± 0.16	1.76 ± 0.22	1.68 ± 0.17	0.504
ALT folds (N: 0–41 IU)	33.3 ± 16.75	32.9 ± 15.07	33.3 ± 18.82	0.975
AST folds (N: 0–37 IU)	40.63 ± 25.37	41 ± 20.31	40 ± 29.79	0.401
AFP	5.4 ± 3.21	8 ± 3.79	5.4 ± 2.63	0.816
Serum creatinine (0.7–1.2 mg/dl)	1.05 ± 0.15	0.92 ± 0.23	1.04 ± 0.30	0.841
Jaundice	18 (60 %)	22 (73.3 %)	21 (70 %)	0.26
Encephalopathy	14 (46.7 %)	12 (40 %)	13 (43.3 %)	0.81
Lower limb oedema	20 (67.7 %)	20 (67.7 %)	19 (63.3 %)	0.45
Bleeding tendency	23 (76.7 %)	24 (80 %)	22 (73.3 %)	0.56
Haematemesis	14 (46.7 %)	13 (43.3 %)	15 (50 %)	0.82

Data presented as number (percent) or mean ± standard deviation. None of these parameters showed significant differences among the three groups

AFP α-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, INR International Normalized Ratio, TLC total leucocyte count